PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcgastBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Gastroenterology
 
BMC Gastroenterol. 2012; 12: 95.
Published online Jul 28, 2012. doi:  10.1186/1471-230X-12-95
PMCID: PMC3444408
CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Ching-Shya Yong,1 Chih-Ming Ou Yang,corresponding author1 Yenn-Hwei Chou,1 Chao-Sheng Liao,1 Chung-Wei Lee,2 and Chin-Cheng Lee3
1Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, No.95, Wen Chang Road, Shih Lin District, Taipei City, 11120, Taiwan
2Department of Biological Engineering, Massachusetts Institute of Technology, Massachusetts, USA
3Department of Pathology, Shin Kong Wu Ho-Su Memorial Hospital, No.95, Wen Chang Road, Shih Lin District, Taipei City, 11120, Taiwan
corresponding authorCorresponding author.
Ching-Shya Yong: Lihuihui1970/at/163.com; Chih-Ming Ou Yang: jimmyouyang/at/hotmail.com; Yenn-Hwei Chou: Wangjiaheng1970/at/163.com; Chao-Sheng Liao: Tangbeibei1970/at/163.com; Chung-Wei Lee: Cuiyifan2006/at/163.com; Chin-Cheng Lee: Tangfeifei1111/at/163.com
Received March 27, 2012; Accepted July 17, 2012.
Abstract
Background
To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has not yet been identified.
Methods
We retrospectively reviewed the hospital records of patients with gastric cancer. Among 500 patients receiving curative resection, 95 patients had recurrence. Twenty patients from the recurrence group (95 patients) and 20 patients from the non-recurrence group (405 patients) were randomly selected and identified as “study” and “control” groups, respectively. We reviewed patients’ histological study of CD44/CD24 expression by performing immunohistochemistry and recurrence rate.
Results
Study group had higher TNM stage (III-IV) than control group (80% vs. 25%, P = 0.001). Proportion of lymph node metastasis was significantly higher in study group than that in control group (90% vs. 45%, P = 0.002), and proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in study group than in control group (45% vs. 15%, P = 0.007). Univariate analysis revealed no difference in risk of gastric cancer recurrence between CD44+ and CD44- patients (OR = 1.00, 95% CI: 0.29-3.45, P =1.000). CD24+ patients showed no greater significance of gastric cancer recurrence than CD24- patients (OR = 1.86, 95% CI: 0.52-6.61, P = 0.339). After adjusting for other risk factors, the association of CD44 expression (aOR = 0.66, 95% CI: 0.10-4.26, P = 0.658), CD24 expression (aOR = 0.09, 95% CI: 0.01-1.35, P = 0.081) or combined (CD44/CD24) with gastric cancer recurrence were not significant.
Conclusion
Neither individual expression of CD24 or CD44, nor combined expression of CD44/CD24 was associated with recurrence of gastric carcinoma.
Keywords: CD44, CD24, Prognosis, Recurrent gastric cancer
Articles from BMC Gastroenterology are provided here courtesy of
BioMed Central